BioCryst closes $700M Astria acquisition, adds Phase 3 HAE asset navenibart

BIOCRYST PHARMACEUTICALS INC

Acquired Astria for ~$700M net of cash; financed with $396.6M Blackstone loan and 37.3M shares.
Adds navenibart (Phase 3 plasma kallikrein inhibitor) offering every-3/6-month HAE dosing.
Astria CEO Jill Milne joins BioCryst board; John Ruesch becomes Chief Technical Operations Officer.
BioCryst obtained $400M term loan from Blackstone funds (5-yr, SOFR+4.5% with PIK option).
Astria's nine-month 2025 net loss $98.4M; had $227.7M cash/investments at Sep 30, 2025.

item 1.01item 2.01item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.